Modification of bile acids metabolism with multi-strain probiotic in patients with diarrhea predominant irritable bowel syndrome: a randomized study

Artem Neverovskyi; Serhii Polishchuk

doi:10.32345/USMYJ.4(142).2023.55-61

Artem Neverovskyi Department of internal medicine No1, Bogomolets National Medical University, Kyiv, Ukraine. https://orcid/org/0000-0002-2618-6347
Serhii Polishchuk Department of internal medicine No1, Bogomolets National Medical University, Kyiv, Ukraine. https://orcid/org/0000-0001-6926-9911

DOI: https://doi.org/10.32345/USMYJ.4(142).2023.55-61

Keywords: Bile Acids аnd Salts, Diarrhea, Irritable Bowel Syndrome, Malabsorption Syndromes, Probiotics

Abstract

one of the irritable bowel syndrome with diarrhea (IBS-D) mechanisms of development is bile acids (BA) malabsorption (BAM). The promising new therapeutic approach for BAM – probiotic bacteria producing bile salt hydrolase (BSH). The aim of the study was to compare the effect of multi-strain probiotic and cholestyramine combination with cholestyramine monotherapy on modifying the parameters of BA metabolism in IBS-D patients. Materials and methods. The trial was conducted as a randomized, open, parallel study and included 108 patients with IBS-D divided into 2 groups: case group (n=57) that received combination of probiotic (L. rhamnosus, L. plantarum, S. thermophilus, L. acidophilus, B. bifidum, B. longum, B. infantis, S. boulardii) with cholestyramine, and control group (n=51) that received cholestyramine monotherapy during 12 weeks. The total relative activity (RA) of gut bacterial BSH, serum BA (sBA) and fecal BA (fBA) were assessed in all patients. Results: total, primary and secondary sBA and fBA, proportions of primary and secondary fBA were significantly different after 12 weeks within each group comparing to baseline, p<0.05. In case group the proportions of primary and secondary sBA, RA of gut bacterial BSH were significantly different after 12 weeks comparing to baseline, p<0.05. All the parameters of BA metabolism except absolute levels of secondary sBA were significantly different after 12 weeks between the control and case groups, p<0.05. Conclusions: combination of cholestyramine and multi-strain probiotic led to more pronounced alterations of BA metabolism and increasing of gut bacterial BSH-activity comparing to cholestyramine monotherapy. It may explain possible mechanism of action of probiotics in patients with IBS-D and assumed BAM.

References

Boonma, P., Shapiro, J. M., Hollister, E. B., Badu, S., Wu, Q., Weidler, E. M., Abraham, B. P., Devaraj, S., Luna, R. A., Versalovic, J., Heitkemper, M. M., Savidge, T. C., & Shulman, R. J. (2021). Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome. Frontiers in pain research (Lausanne, Switzerland), 2, 691689. https://doi.org/10.3389/fpain.2021.691689.

Camilleri M. (2015). Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut and liver, 9(3), 332–339. https://doi.org/10.5009/gnl14397.

Camilleri, M., Acosta, A., Busciglio, I., Boldingh, A., Dyer, R. B., Zinsmeister, A. R., Lueke, A., Gray, A., & Donato, L. J. (2015a). Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Alimentary pharmacology & therapeutics, 41(5), 438–448. https://doi.org/10.1111/apt.13065.

Dior, M., Delagrèverie, H., Duboc, H., Jouet, P., Coffin, B., Brot, L., Humbert, L., Trugnan, G., Seksik, P., Sokol, H., Rainteau, D., & Sabate, J. M. (2016). Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 28(9), 1330–1340. https://doi.org/10.1111/nmo.12829.

Drossman D. A. (2016). Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology, S0016-5085(16)00223-7. Advance online publication. https://doi.org/10.1053/j.gastro.2016.02.032.

Farrugia, A., & Arasaradnam, R. (2020). Bile acid diarrhoea: pathophysiology, diagnosis and management. Frontline gastroenterology, 12(6), 500–507. https://doi.org/10.1136/flgastro-2020-101436.

Fukudo, S., Okumura, T., Inamori, M., Okuyama, Y., Kanazawa, M., Kamiya, T., Sato, K., Shiotani, A., Naito, Y., Fujikawa, Y., Hokari, R., Masaoka, T., Fujimoto, K., Kaneko, H., Torii, A., Matsueda, K., Miwa, H., Enomoto, N., Shimosegawa, T., & Koike, K. (2021). Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. Journal of gastroenterology, 56(3), 193–217. https://doi.org/10.1007/s00535-020-01746-z.

Holtmann, G. J., Ford, A. C., & Talley, N. J. (2016). Pathophysiology of irritable bowel syndrome. The lancet. Gastroenterology & hepatology, 1(2), 133–146. https://doi.org/10.1016/S2468-1253(16)30023-1.

Jones, M. L., Martoni, C. J., & Prakash, S. (2012). Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. European journal of clinical nutrition, 66(11), 1234–1241. https://doi.org/10.1038/ejcn.2012.126.

Joyce, S. A., MacSharry, J., Casey, P. G., Kinsella, M., Murphy, E. F., Shanahan, F., Hill, C., & Gahan, C. G. (2014). Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proceedings of the National Academy of Sciences of the United States of America, 111(20), 7421–7426. https://doi.org/10.1073/pnas.1323599111.

Li, B., Zhang, J., Chen, Y., Wang, Q., Yan, L., Wang, R., Wei, Y., You, Z., Li, Y., Miao, Q., Xiao, X., Lian, M., Chen, W., Qiu, D., Fang, J., Gershwin, M. E., Tang, R., & Ma, X. (2021). Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis. Gut microbes, 13(1), 1946366. https://doi.org/10.1080/19490976.2021.1946366.

Li, X., Xiao, Y., Huang, Y., Song, L., Li, M., & Ren, Z. (2022). Lactobacillus gasseri RW2014 Ameliorates Hyperlipidemia by Modulating Bile Acid Metabolism and Gut Microbiota Composition in Rats. Nutrients, 14(23), 4945. https://doi.org/10.3390/nu14234945.

Lye, H. S., Kato, T., Low, W. Y., Taylor, T. D., Prakash, T., Lew, L. C., Ohno, H., & Liong, M. T. (2017). Lactobacillus fermentum FTDC 8312 combats hypercholesterolemia via alteration of gut microbiota. Journal of biotechnology, 262, 75–83. https://doi.org/10.1016/j.jbiotec.2017.09.007.

Mearin, F., Lacy, B. E., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016). Bowel Disorders. Gastroenterology, S0016-5085(16)00222-5. Advance online publication. https://doi.org/10.1053/j.gastro.2016.02.031.

Min, Y. W., Rezaie, A., & Pimentel, M. (2022). Bile Acid and Gut Microbiota in Irritable Bowel Syndrome. Journal of neurogastroenterology and motility, 28(4), 549–561. https://doi.org/10.5056/jnm22129.

Polishchuk, S., & Neverovskyi, A. (2023). Efficacy of bile salt hydrolase synthesizing probiotic bacteria in the treatment of irritable bowel syndrome with diarrhea. GASTROENTEROLOGY, 57(2), 108–114. https://doi.org/10.22141/2308-2097.57.2.2023.540.

Sadowski, D. C., Camilleri, M., Chey, W. D., Leontiadis, G. I., Marshall, J. K., Shaffer, E. A., Tse, F., & Walters, J. R. F. (2020). Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 18(1), 24–41.e1. https://doi.org/10.1016/j.cgh.2019.08.062.

Savarino, E., Zingone, F., Barberio, B., Marasco, G., Akyuz, F., Akpinar, H., Barboi, O., Bodini, G., Bor, S., Chiarioni, G., Cristian, G., Corsetti, M., Di Sabatino, A., Dimitriu, A. M., Drug, V., Dumitrascu, D. L., Ford, A. C., Hauser, G., Nakov, R., Patel, N., … Barbara, G. (2022). Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European gastroenterology journal, 10(6), 556–584. https://doi.org/10.1002/ueg2.12259.

Sperber, A. D., Bangdiwala, S. I., Drossman, D. A., Ghoshal, U. C., Simren, M., Tack, J., Whitehead, W. E., Dumitrascu, D. L., Fang, X., Fukudo, S., Kellow, J., Okeke, E., Quigley, E. M. M., Schmulson, M., Whorwell, P., Archampong, T., Adibi, P., Andresen, V., Benninga, M. A., Bonaz, B., … Palsson, O. S. (2021). Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology, 160(1), 99–114.e3. https://doi.org/10.1053/j.gastro.2020.04.014.

Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., Moss-Morris, R., Yiannakou, Y., & Ford, A. C. (2021). British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut, 70(7), 1214–1240. https://doi.org/10.1136/gutjnl-2021-324598.

Vijayvargiya, P., Camilleri, M., Carlson, P., Nair, A., Nord, S. L., Ryks, M., Rhoten, D., Burton, D., Busciglio, I., Lueke, A., Harmsen, W. S., & Donato, L. J. (2020). Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 18(13), 2962–2970.e6. https://doi.org/10.1016/j.cgh.2020.02.027.

Wang, L., Zhang, J., Guo, Z., Kwok, L., Ma, C., Zhang, W., Lv, Q., Huang, W., & Zhang, H. (2014). Effect of oral consumption of probiotic Lactobacillus planatarum P-8 on fecal microbiota, SIgA, SCFAs, and TBAs of adults of different ages. Nutrition (Burbank, Los Angeles County, Calif.), 30(7-8), 776–83.e1. https://doi.org/10.1016/j.nut.2013.11.018.

Yoshikazu Kinoshita, Tsuyoshi Sanuki, Sachiko Oouchi, Kousaku Kawashima & Shunji Ishihara (2021). Bile Acid Diarrhea: An Etiology of Chronic Diarrhea Easily Overlooked. Shimane J. Med. Sci., 38, 89-97. https://doi.org/10.51010/sjms.38.3_89.

Zampa, A., Silvi, S., Fabiani, R., Morozzi, G., Orpianesi, C., & Cresci, A. (2004). Effects of different digestible carbohydrates on bile acid metabolism and SCFA production by human gut micro-flora grown in an in vitro semi-continuous culture. Anaerobe, 10(1), 19–26. https://doi.org/10.1016/j.anaerobe.2003.12.002.

Zhan, K., Zheng, H., Li, J., Wu, H., Qin, S., Luo, L., & Huang, S. (2020). Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome. BioMed research international, 2020, 3828249. https://doi.org/10.1155/2020/3828249.